Immatics Plans FDA Submission for Anzu-Cel in 2027

Immatics announced plans to submit its cell therapy Anzu-Cel for FDA approval in 2027, targeting precision oncology treatment advancements.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.